<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120961</url>
  </required_header>
  <id_info>
    <org_study_id>KY20190823-05</org_study_id>
    <nct_id>NCT04120961</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After ePCI (COBER Study)</brief_title>
  <official_title>Safety and Efficacy of Delayed Continuous Use of Bivalirudin 4 Hours After Elective PCI in Patients With CHD (COBER Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the development of percutaneous coronary intervention (PCI) in patients with coronary
      heart disease (CHD), unfractionated heparin (UFH) and low molecular weight heparin (LWMH)
      have been the preferred anticoagulants in peri-operative period. However, UFH has some
      defects, such as incomplete and unstable inhibition of thrombin, large individual
      differences, multiple monitoring of activated coagulation time (ACT), ineffective thrombin
      binding to fibrin, non-specific protein binding and induced thrombocytopenia (HIT). Compared
      with UFH, LWMH has lower non-specific protein binding rate, but it is not superior to UFH in
      efficacy, hemorrhage and HIT.

      Bivalirudin can bind specifically to thrombin catalytic site and anionic external binding
      site, directly inhibit thrombin activity, thereby inhibiting thrombin-catalyzed and induced
      reactions. At the same time, thrombin can also inactivate it by enzymatic hydrolysis of
      bivalirudin. Therefore, the inhibition of bivalirudin on thrombin is reversible and
      transient, and the risk of bleeding after drug withdrawal is relative small. It has been
      reported that bivalirudin can significantly reduce the risk of peri-operative bleeding during
      PCI period compared with UFH. Clopidogrel had not yet played a role in most patients after
      emergency PCI, and there was a &quot;blank period&quot; for 2-4 hours without effective antithrombotic
      concentration, which was also the peak period of acute stent thrombosis. Han and coworkers
      have shown that for acute myocardial infarction (AMI) patients undergoing emergency PCI,
      whether or not glycoprotein IIb/IIIa inhibitors were added, delayed peri-operative injection
      of bivalrudin was significantly better than UFH in terms of net clinical adverse event.
      However, for patients with elective PCI (ePCI), delayed bivalirudin injection was only used
      in some patients in REPLACE-2 and ISAR-REACT-3 studies, and the delayed time of bivalrudin
      use after ePCI was not definite.

      Therefore, in the current study we aim to explore the efficacy and safety of delayed
      bivalirudin injection 4 hours after elective PCI in patients with CHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed as a single-center, randomized and prospective study aiming to
      evaluate the safety and efficacy of delayed continuous use of bivalirudin 4 hours after ePCI
      for the treatment of peri-operative myocardial injury (PMI) compared with bivalirudin use
      during ePCI. Based on previous study reported and estimated 10% loss follow-up of these
      patients in each arm, a total of 330 patients with CHD were required in our study, and with
      165 patients per group as a ratio of 1:1 randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate of PMI in CHD patients 3 days after ePCI</measure>
    <time_frame>Clinical follow up at 3 days after ePCI</time_frame>
    <description>the incidence rate of PMI indicated by the changes of myocardial injury biomarkers (such as TNI and CK-MB) in CHD patients between delayed continuous use of bivalirudin and bivalirudin use during ePCI groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of patient-related ischemic events and bleeding</measure>
    <time_frame>Clinical follow up at 30 days, 6, 9 and 12 months after the operation</time_frame>
    <description>The incidence rate of patient-related ischemic events including all myocardial infarction , any revascularization and all-cause death, and bleeding between delayed continuous use of bivalirudin and bivalirudin use during ePCI groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>delayed continuous use of bivalirudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 165 patients are assigned to group with delayed continuous use of bivalirudin after randomization schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bivalirudin use during ePCI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A total of 165 patients are assigned to group with bivalirudin use during ePCI after randomization schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>delayed continuous use of bivalirudin</intervention_name>
    <description>delayed continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)</description>
    <arm_group_label>delayed continuous use of bivalirudine</arm_group_label>
    <other_name>delayed continuous use of bivalirudin 4 hours after elective PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalirudin use during ePCI</intervention_name>
    <description>bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)</description>
    <arm_group_label>bivalirudin use during ePCI</arm_group_label>
    <other_name>bivalirudin use during ePCI period</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective PCI

          -  Preoperative score of CRUSADE &gt; 30 or suspected or confirmed HIT patients

        Exclusion Criteria:

          -  PCI within 1 month

          -  Complicated with blood or rheumatism and immune system diseases

          -  Life expectancy no more than 1 year or factors causing difficulties in clinical follow
             up

          -  A history of peptic ulcer or GI bleeding in the previously

          -  Stroke within 6 months prior to the operation

          -  A history of severe hepatic or renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiming Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiming Wu, MD</last_name>
    <phone>+86 18001599783</phone>
    <email>wuzhiming1997@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiangqi Wu, MD</last_name>
    <phone>+86 15250997876</phone>
    <email>15250997876@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital, Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Zhou</last_name>
      <phone>+86 13913893984</phone>
      <email>565219791@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.</citation>
    <PMID>25775052</PMID>
  </reference>
  <reference>
    <citation>Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.</citation>
    <PMID>12588269</PMID>
  </reference>
  <reference>
    <citation>Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, Richardt G, Berger PB, Sch√∂mig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3 Trial Investigators. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J. 2010 Mar;31(5):582-7. doi: 10.1093/eurheartj/ehq008. Epub 2010 Feb 11.</citation>
    <PMID>20150324</PMID>
  </reference>
  <reference>
    <citation>Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S; POISE (PeriOperative ISchemic Evaluation) Investigators. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011 Apr 19;154(8):523-8. doi: 10.7326/0003-4819-154-8-201104190-00003.</citation>
    <PMID>21502650</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bivalirudin</keyword>
  <keyword>delayed use</keyword>
  <keyword>peri-operative myocardial injury</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hirudins</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

